BALTIMORE — Lupin on Monday announced the appointment of Theresa Stevens as chief corporate development officer for its global operations. Stevens will assume full responsibility for global merger and acquisitions and specialty business strategy. Stevens has more than 27 years of experience in the pharmaceutical and biotech sector, with significant experience in managing strategy, corporate development, M&A and licensing.
“I am very pleased to welcome Theresa to the Lupin family," said Vinita Gupta, Lupin CEO. "I am sure her rich experience in the areas of M&A and specialty strategy within the pharmaceutical and biotech industry sector will help Lupin’s growth plans.”
Prior to joining Lupin, Stevens was with Aptalis as the chief corporate development officer responsible for M&As, strategy and global business development. Before Aptalis, Stevens was with Novartis for more than nine years, and held positions of increasing responsibility including head, global BD&L for general medicines, executive director and head, global BD&L for respiratory and dermatology business units and head U.S. business development and licensing, life cycle management and generic brand strategies.
Stevens has a masters degree in biochemistry from University of Maryland and is a Juris Doctor from the Widener University School of Law. She started her career as a research scientist at Dupont and has practiced corporate law at Pennie & Edmonds.
Earlier this year, Lupin had appointed Maurice Chagnaud as president-Europe and head of inhalation strategy. He had joined from Teva, where he was the VP Central and Eastern Europe. Lupin has been in the middle of preparing for a bigger push globally and is looking to take a deeper dive into the U.S. and European markets as well as fast growing emrging markets like Mexico, Brazil, Russia and China. The company also is targeting niche segments like inhalation, which is valued at more than $23 billion in annual sales, Lupin reported, citing IMS sales data.
The company, which is in the middle of setting up a dedicated inhalation research facility in the United States, had earlier this year appointed Xian-Ming Zeng as SVP inhalation research and development. Xian-Ming also joined Lupin from Teva, where he was VP global respiratory R&D in the branded pharmaceutical products division since 2007.